How Much Sugar Should Be Reduced To The Best?

Diabetes, is its rising prevalence, has become a serious threat to human health, the prevalence of diseases. According to the World Diabetes Federation in 2007 released data show that China now has 39.8 million diabetic patients, is expected by 2025 will reach 59.3 million, of which 90% to 95% of type 2 diabetes; cardiovascular disease, kidney and retina microvascular disease is the most common complications of type 2 diabetes is leading cause of death, cause of disability. Recalling the past, clinical research of diabetes, before the people of the two problems to be solved: type 2 diabetes blood sugar level should drop much? Whether intensive glucose control can reduce the vascular complications? Current treatment guidelines and the International Diabetes Federation guidelines of diabetes type 2 diabetic patients are recommended glycosylated hemoglobin should be controlled to below 6.5%, but this is mainly the result of speculation based on epidemiological data, the results confirm that there is no drug intervention, the medical profession are In looking forward to seeing the new evidence-based treatment strategies for clinical medical research to provide more solid evidence.

Beijing June 7, 2008, the American Diabetes Association (ADA) 68th Annual Meeting from 20 countries, 11,140 cases of type 2 diabetes participated, the largest ever diabetes study - ADVANCE study. Well-known New England Journal of Medicine also published the findings. ADVANCE study with cardiovascular risk factors for type 2 diabetes to reduce the glycated hemoglobin value of less than 6.5% target for the treatment, evaluation of intensive blood glucose control can further reduce the variety of vascular complications. After five years of observation, the study confirmed to gliclazide MR (gliclazide extended-release tablets) enhanced glucose-based programs to achieve a safe hypoglycemic standards, a significant reduction in major macrovascular and microvascular composite end point risk up to 10%, the end points included cardiovascular death, diabetes, kidney disease events and the most common complications of diabetes, including kidney disease by up to 21%, 30% reduction in proteinuria, which is the major predictor of cardiovascular mortality reduction factors. Meanwhile, the study of severe hypoglycemia in the UKPDS study of the occurrence rate of only 1 / 3, which also demonstrate the good safety of the treatment program. Thus, patients can order gliclazide sustained-release tablets based on a comprehensive program to strengthen the benefit of hypoglycemic.

ADVANCE study results for the development of future diabetes treatment strategies provide an important basis and therefore a landmark. Concern is that one-third of the study patients from China, Chinese diabetes treatment strategies will no doubt provide a more adequate and convincing evidence. The latest by the Chinese Medical Association Diabetes will be issued by the Chinese type 2 diabetes prevention and treatment guidelines, patients with diabetes to control blood sugar clear that the goal is less than 6.5% glycated hemoglobin, which is the goal of ADVANCE glucose. Therefore, ADVANCE study used to gliclazide sustained-release tablets enhance glucose-based solutions, safe, effective and worthy of further promotion.